Product Description: DW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia[1].
Applications: COVID-19-immunoregulation
Formula: C20H28N6O2
References: [1]Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.
CAS Number: 2241311-72-6
Molecular Weight: 384.48
Compound Purity: 97.70
Research Area: Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Epigenetic Reader Domain